Obesity trial gets underway for Pila Pharma

2026-10-01 14:41:00

Pila Pharma has activated the clinical site that will conduct the first part of PP-CT04, the company’s twelve-week trial of its oral TRPV1 antagonist XEN-D0501 in obesity. The site was given permission to start enrolling participants in the initial safety cohort of eight and screened 6 participants on its first day.

Read the full article at biostock.se:

https://biostock.se/en/2026/10/obesity-trial-gets-underway-for-pila-pharma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.